Clinical trials: Cytomegalovirus Disease
HIV Infections, Acquired Immunodeficiency Syndrome
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed.
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- CRRT (NCT00000134)
- Testing
- Ganciclovir, Foscarnet
- Volunteers
- 279 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Lung Transplant; Complications
Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)
Background: Lung transplant recipients (LTR) have the highest risk of CMV infection. CMV pneumonitis, lymphocytic bronchitis, and detection of CMV DNA in bronchoalveolar lavage fluid are independent risk factors for the…
- Trial name
- NCT04377139
- Testing
- Prophylaxis, Preemptive
- Volunteers
- 1,500 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Cytomegalovirus Infection
Study of Prophylactic Vs Preemptive Valganciclovir
This is a study of prophylactic Vs preemptive oral valganciclovir for management of cytomegalovirus infection in adult renal transplant recipients looking at clinical and pharmacoeconomic outcomes
- Trial name
- NCT00374686
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Washington University School of Medicine
Cytomegalovirus Infection
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks.
- Trial name
- NCT00942305
- Testing
- Brincidofovir
- Where
- 26 sites in United States
- Volunteers
- 239 people
- Sponsor
- Jazz Pharmaceuticals
Cytomegalovirus Infections
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain…
- Trial name
- NCT00241345
- Testing
- Valganciclovir, Ganciclovir
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Cytomegalovirus Infections
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
The purpose of this study is to evaluate the benefits and safety of the antiviral drug ganciclovir (DHPG) given intravenously to treat newborn infants who are born infected with cytomegalovirus (CMV).
- Trial name
- NCT00001100
- Testing
- ganciclovir
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either uveitis or endotheliitis, will be started on 2% guttae ganciclovir, 1 drop 5 times a day for 6 weeks.
- Trial name
- NCT02943057
- Testing
- 2% guttae ganciclovir
- Where
- Singapore
- Volunteers
- 25 people
- Sponsor
- Singapore National Eye Centre
Patients Undergoing Allogeneic Stem Cell Transplantation
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
In patients after allogeneic stem cell transplantation reactivation of latent herpesviruses such as Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) is a frequent and life threatening complication requiring antiviral treatment.
- Trial name
- NCT02227641
- Testing
- CMV/EBV specific T-cell
- Where
- 6 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School